COMBINATION TOCA 511 & 5-FC SIGNIFICANTLY EXTENDS SURVIVAL IN A MURINE ORTHOTOPIC MODEL OF IN rRACEREBELLAR MEDULLOBLAS TOMA

被引：0
|
作者：
Richardson, Angela [1 ]
Collins, Sara [2 ]
Inagaki, Akhito [2 ]
Armstrong, Valerie [3 ]
Roussel, Martine [4 ]
Robbins, David [3 ]
Ayad, Nagy [3 ]
Jolly, Douglas [5 ]
Kasahara, Noriyuki [2 ]
机构：
[1] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Miami, Miami, FL USA
[4] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
[5] Tocagen Inc, San Diego, CA USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
THER-30
引用
收藏
页码：120 / 120
页数：1
相关论文
共 7 条
  • [1] The addition of toca 511 and 5-FC to temozolomide improves response in a temozolomide-resistant murine glioblastoma model and correlates with toca 511 dose
    Rodriguez-Aguirre, Maria E.
    Viaud, Sophie
    Mendoza, Daniel
    Montellano, Tiffany
    Ostertag, Derek G.
    Gruber, Harry
    Jolly, Douglas
    Bentley, Cornelia
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Toca 511 and 5-FC in Combination with Metronomic Cyclophosphamide Reduces Treg Cells and Enhances Therapy Efficacy in a Preclinical Murine Model
    Montellano, Tiffany T.
    Viaud, Sophie
    Mendoza, Daniel
    Rodriguez-Aguirre, Maria
    Gruber, Harry
    Jolly, Douglas
    Ostertag, Derek
    JOURNAL OF NEUROSURGERY, 2019, 131 (01)
  • [3] Toca 511/5-FC Treatment Has the Potential to Increase the Therapeutic Efficacy of Anti-PD-1 Antibody in an Immunocompetent Murine Pancreatic Cancer Model
    Niwa, Hiroki
    Nakamura, Toru
    Kushiya, Hiroki
    Suzuki, Tomohiro
    Inoko, Kazuho
    Hiraoka, Kei
    Inagaki, Akihito
    Tsuchikawa, Takahiro
    Shichinohe, Toshiaki
    Noriyuki, Kasahara
    Hirano, Satoshi
    MOLECULAR THERAPY, 2023, 31 (04) : 298 - 298
  • [4] Therapeutic efficacy of anti-tumor immune responses activated by Toca 511/5-FC treatment in pancreatic cancer model
    Niwa, Hiroki
    Nakamura, Toru
    Kushiya, Hiroki
    Inoko, Kazuho
    Hiraoka, Kei
    Inagaki, Akihito
    Tsuchikawa, Takahiro
    Shichinohe, Toshiaki
    Jolly, Douglas
    Kasahara, Noriyuki
    Hirano, Satoshi
    CANCER SCIENCE, 2021, 112 : 808 - 808
  • [5] T cell priming by Toca 511 and 5-FC coupled with T regulatory cell depletion by aCTLA-4 synergistically enhances anti-tumor immune memory in a mouse model of glioma
    Mitchell, Leah
    Yagiz, Kader
    Munday, Anthony
    Lopez, Fernando
    Mendoza, Daniel
    Jolly, Douglas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [6] TOCA 511 AND 5-FC INDUCES T CELL-MEDIATED ANTITUMOR IMMUNITY IN A MOUSE GLIOMA MODEL WHICH IS ENHANCED BY THE ADDITION OF A THERAPEUTIC ANTIBODY AGAINST CTLA-4 AND CORRELATIVE WITH A REDUCTION IN MEMORY T REGULATORY CELLS.
    Jolly, Douglas
    Mitchell, Leah
    Yagiz, Kader
    Espinoza, Fernando Lopez
    Mendoza, Daniel
    Munday, Anthony
    Gruber, Harry
    NEURO-ONCOLOGY, 2017, 19 : 252 - 252
  • [7] Combining Toca 511 and 5-fluorocytosine with αPD-1 or αCTLA-4 antibody significantly reduces tumor burden compared to either checkpoint inhibitor alone or in combination in a subcutaneous mouse glioma model
    Mitchell, Leah
    Espinoza, Fernando Lopez
    Yagiz, Kader
    Mendoza, Daniel
    Rodriguez-Aguirre, Maria
    Mitchell, Sean
    Jolly, Douglas J.
    Robbins, Joan M.
    CANCER RESEARCH, 2016, 76
1